EGFR and non-small cell lung carcinoma: Gefitinib, one of the first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, was approved by the US Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer in 2015 (Kazandjian et al., 2016).